A detailed history of Citigroup Inc transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Citigroup Inc holds 20,606 shares of BMEA stock, worth $87,163. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,606
Previous 21,424 3.82%
Holding current value
$87,163
Previous $96,000 116.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$4.23 - $10.1 $3,460 - $8,261
-818 Reduced 3.82%
20,606 $208,000
Q2 2024

Aug 12, 2024

SELL
$4.14 - $15.3 $1.61 Million - $5.94 Million
-388,134 Reduced 94.77%
21,424 $96,000
Q1 2024

May 10, 2024

BUY
$13.92 - $19.5 $4.96 Million - $6.95 Million
356,365 Added 669.95%
409,558 $6.12 Million
Q4 2023

Feb 09, 2024

SELL
$8.37 - $19.8 $526,816 - $1.25 Million
-62,941 Reduced 54.2%
53,193 $772,000
Q3 2023

Nov 09, 2023

BUY
$13.44 - $23.02 $830,726 - $1.42 Million
61,810 Added 113.78%
116,134 $1.6 Million
Q2 2023

Aug 10, 2023

BUY
$21.66 - $41.8 $180,925 - $349,155
8,353 Added 18.17%
54,324 $1.19 Million
Q1 2023

May 11, 2023

BUY
$6.8 - $32.35 $56,317 - $267,922
8,282 Added 21.97%
45,971 $1.43 Million
Q4 2022

Feb 09, 2023

BUY
$6.3 - $11.6 $223,139 - $410,860
35,419 Added 1560.31%
37,689 $317,000
Q3 2022

Nov 10, 2022

BUY
$9.51 - $13.61 $3,604 - $5,158
379 Added 20.04%
2,270 $22,000
Q2 2022

Aug 10, 2022

SELL
$3.0 - $12.03 $996 - $3,993
-332 Reduced 14.93%
1,891 $23,000
Q1 2022

May 12, 2022

SELL
$4.39 - $9.03 $23,517 - $48,373
-5,357 Reduced 70.67%
2,223 $10,000
Q4 2021

Feb 10, 2022

BUY
$7.22 - $12.72 $44,699 - $78,749
6,191 Added 445.72%
7,580 $56,000
Q3 2021

Nov 10, 2021

BUY
$10.0 - $15.99 $13,890 - $22,210
1,389 New
1,389 $17,000

Others Institutions Holding BMEA

About Biomea Fusion, Inc.


  • Ticker BMEA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,290,600
  • Market Cap $124M
  • Description
  • Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...
More about BMEA
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.